Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glanzmann's thrombasthenia: updated.

Sona Nair1, Kanjaksha Ghosh, Bipin Kulkarni

  • 1Institute of Immunohaematology (I.C.M.R), 13th Floor, K.E.M. Hospital Campus, Parel, Mumbai--400 012, India.

Platelets
|December 19, 2002
PubMed
Summary

Glanzmann's thrombasthenia (GT) is a rare platelet disorder affecting fibrinogen binding. Understanding its varied genetic causes and pathophysiology is crucial for managing patients and developing new treatments, particularly GPIIb-IIIa inhibitors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enteric microbiome and obesity: a multidimensional narrative review.

Microbial genomics·2025
Same author

Identification of a GFI1B variant associated with abnormal platelet function and normal platelet count.

British journal of haematology·2024
Same author

Fibrosis and bone marrow: understanding causation and pathobiology.

Journal of translational medicine·2023
Same author

Editorial: Sickle cell disease in the 21st century-Morbidity to molecular biology.

Frontiers in medicine·2022
Same author

Novel RASGRP2 variants in platelet function defects: Indian study.

British journal of haematology·2022
Same author

Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): Report of two cases and review of literature.

Haemophilia : the official journal of the World Federation of Hemophilia·2022

Area of Science:

  • Hematology
  • Genetics
  • Molecular Biology

Background:

  • Glanzmann's thrombasthenia (GT) is an autosomal recessive platelet function defect.
  • GT is characterized by impaired platelet aggregation due to defects in the GPIIb-IIIa receptor.
  • Clinical manifestations include epistaxis, gum bleeding, and menorrhagia, with rare occurrence of hematoma or hemarthrosis.

Purpose of the Study:

  • To review uncommon features of Glanzmann's thrombasthenia.
  • To discuss current management options for GT patients.
  • To highlight the importance of understanding GT pathophysiology for developing targeted therapies.

Main Methods:

  • Review of literature on Glanzmann's thrombasthenia.
  • Discussion of diagnostic features including platelet count, bleeding time, and aggregation studies.

Related Experiment Videos

  • Analysis of flow cytometry and GPIIb-IIIa receptor studies.

    • Main Results:

    • GT exhibits phenotypic heterogeneity due to various genetic mutations in GPIIb or IIIa genes.
    • Variant forms of GT may have functionally defective glycoproteins despite normal or near-normal amounts.
    • Molecular biology techniques enable carrier and prenatal diagnosis.

    Conclusions:

    • Understanding GT pathophysiology is vital for effective patient management and drug development.
    • GPIIb-IIIa inhibitors, used in coronary artery disease, mimic a temporary GT state.
    • Accurate diagnosis of carriers and fetuses is possible through advanced techniques like PLA1 typing.